Aortic coarctation and late hypertension
Conditions
Interventions
Trade Name: Atacand
Pharmaceutical Form: Tablet
Trade Name: Selokeen
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Sponsors
Department of Cardiology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Diagnosis of aortic coarctation (EPCC code 09.29.01) - Previous repair of aortic coarctation - Age 18-80 years - Current use of anti-hypertensive medication (=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - Known oversensitivity for candesartan or metoprolol - Severe liver insufficiency (ASAT or ALAT >3ULN) - Current use of =3 anti-hypertensive drugs - Pregnancy or wish to become pregnant - General contraindications for use of candesartan - General contraindications for use of metoprolol (i.e. bradycardia, sick sinus syndrome etc)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate whether treatment with the ARB, candesartan, reduce 24-hours systolic BP more effectively than treatment with the betablocker metoprolol in patients with repaired aortic coarctation and late hypertension ;Secondary Objective: To investigate whether treatment with the ARB, candesartan, reduce arterial stiffness as assessed by aortic pulse wave velocity (PWV) more effectively than treatment with the betablocker metoprolol in patients with repaired aortic coarctation and late hypertension To investigate the effects of the antihypertensive agents on several hormones, including components of the renin-angiotensin-aldosteron system, catecholamines and NT-proBNP. ;Primary end point(s): Reduction in 24-hours systolic blood pressure after 8 weeks of active treatment with either candesartan or metoprolol. | — |
Countries
Netherlands
Outcome results
None listed